

## DAFTAR PUSTAKA

1. Tanagho Emil. Urinary obstruction & statis. In : Mc Aninch Jack, Tanagho Emil, editors. Smith's General Urology. 18th edition. US : McGraw Hill Medica l; 2015, p 166-79.
2. Dhingra Neelime, Bhagwat Deepak. Benign Prostatic Hiperplasia. An Overview of existing treatment. Indian Journal of pharmacology. India ; 2011 p.6-12.
3. Purnomo Basuki. Hiperplasia Prostat Benigna. Dalam : Purnomo Basuki, editor. Dasar-dasar urologi. Edisi ke-3, Malang ; Sagung seto. 2015. Hal. 125-44.
4. Roehrborn C.G., & McConnell J.D. Etiology, Pathophysiology, Epidemiology, and Natural History of Benign Prostatic Hyperplasia. In Walsh P.C., Retik A.B., Vaughan E.D Jr., Wein A.J., et al (Eds). Campbell-Walsh Urology 11th ed . 2015 :1297-1336. Philadelphia: Elsevier.
5. Parsons JK: Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010;5:212-18.
6. Tjahjodjati et al. Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak. Edisi ke-3, Jakarta: Ikatan Ahli Urologi Indonesia. 2017 ; Hal 2.
7. Zul, Muhammad Ilham. Analisis Faktor Resiko Penyakit Benign Prostate Hyperplasia (BPH) pada pasien di RSUP DR. M. DJAMIL Padang Tahun 2019. Padang: Fakultas Keperawatan Universitas Andalas. 2019 : Hal 6.
8. Dmochowski R.R. Bladder Outlet Obstruction: Etiology and Evaluation. Reviews in Urology. 2005;7(6):3-13.
9. Presti J.C. Neoplasms of the prostate gland. In Tanagho E.A., & McAninch J.W. (Eds). Smith's General Urology 17th ed.New York: Lange Medical Books, Mc Graw-Hill. Reis. 2008:pp.367-385.

10. Lee A., Lee H.J., Lim K.B., Huang H.H., Ho H., & Foo K.T. Can Intravesical Prostatic Protrusion Predict Bladder Outlet Obstruction even in Men with Good Flow? *Asian Journal of Urology*. 2015;3:39-43.
11. Terris M.K. Ultrasonography and biopsy of the prostate. In Walsh P.C., Retik A.B., Vaughan E.D Jr., Wein A.J., et al (Eds). *Campbell-Walsh Urology 11th ed.* Philadelphia: Elsevier. 2015:3038-3054.
12. Reis O.L., Barreiro G.C., Baracat J., Prudente A., & D'Ancona C. Intravesical Protrusion of the Prostate as a Predictive Method of Bladder Outlet Obstruction. *International Brazil Journal of Urology*. 2008;34(5):627-637.
13. Hoo K.N., Ayob M.A., Salim M.I., Abduljabbar H.N., & Supriyanto E. 2014. Prostat Volume Measurement Using Transabdominal Ultrasound Scanning. *Advances in Environment Biotechnology and Biomedicine*. 2014;4:336-341.
14. Lee L.S., Sim H.G., Lim K.B., Wang D., & Foo K.T. Intravesical Prostatic Protrusion Predicts Clinical Progression of Benign Prostatic Enlargement in Patients receiving Medical Treatment. *International Journal of Urology*. 2010;17:69-74.
15. Tanguay S, Awde M, Brock G, Casey R, Kozak J, Lee J, et al. Diagnosis and management of benign prostatic hyperplasia in primary care. *Can Urol Assoc J*. 2009 Jun;3(3 Suppl 2):S92-S100.
16. Mohtar A.C, Umbas R. Soebadi, etc. 2017. Panduan Penatalaksanaan Klinis Benign Prostatic Hyperplasia (BPH). Retrieved from Ikatan Ahli rologi Indonesia (IAUI) website : <http://www.iaui.or.id>
17. Shin S.H, Kim J.W, Kim J.W, Oh M.M, Moon D.G. Defining the Degree of Intravesical Prostatic Protrusion in Association With Bladder Outlet Obstruction. *Korean Journal of Urology*. 2013;54:369-372.

18. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. *BJU Int.* 2008;101(3):17-21.
19. Pintarelli VL, Gomes LF, Lorenzetti F, Neto JT, Dambros M. Elderly men's quality of life and lower urinary tract symptoms: an intricate relationship. *BJU Int.* 2011.
20. Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. Dalam: *Campbell's urology*, edisi ke 10. Editor: Walsh PC, Retik AB, Vaughan ED, dan Wein AJ. Philadelphia: WB Saunders Co. 2012:2570-91.
21. Amalia R, Hadisaputro S, Muslim R. Faktor--faktor resiko terjadinya pembesaran prostat jinak (studi kasus di RS. Dr. Kariadi, RSI Sultan Agung, RS Roemani Semarang). Diunduh dari :[http://eprints.undip.ac.id/19133/1/Rizki\\_Amalia.pdf](http://eprints.undip.ac.id/19133/1/Rizki_Amalia.pdf) pada tanggal 28 September 2020, pukul 18.32.
22. Nandeesh H. Benign Prostatic Hyperplasia: dietary and metabolic risk factors. *ntI Urol Nephrol.* 2008;40: 649-56.
23. Chungtai B, Lee R, Te A, Kaplan S. Role of Inflammation in Benign Prostatic Hyperplasia. *Rev Urol.* 2011;13(3):147-50.
24. Oelke M, Hofner K, Jonas U, et al. Benign prostatic hyperplasia: terminology and assessment. *Dtsch Arztebl* 2007;104(33): A 2261-7.
25. Chapple C, Abrams P. Male lower urinary tract symptoms (LUTS) an international consultation on male LUTS Fukuoka, Japan, September 30 October 4, 2012. Monreal: Societe Internationale d'Urologie. 2013.hal.42-3.
26. Grava S, Bachmann A, Descazeaud, etc. Guidelines on the management of Non-neurgenic male lower Urinary tract symptoms (LUTS),incl. Benign Prostatic obstruction (BPO). European Association of Urology 2020.

27. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. *J Urol.* 2011 May;185(5):1793-803. Doi: 10.1016/j.juro.2011.01.074. Epub 2011 Mar 21.
28. Gerber GS, Brendler CB. Evaluation of the Urologic Patient:History, Physical Examination, and Urinalysis. In: *Campbell-Walsh Urology.* 10th Edition. Philadelphia: Elsevier Saunders 2012:71-80.
29. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. *J Urol.* 148: 1549, 1992
30. Liu CC, Wang CJ, Huang SP, Chou YH, Wu WJ, Huang CH. Relationships between American Urological Association symptom index, prostate volume, and disease-specific quality of life question in patients with benign prostatic hyperplasia. *Kaohsiung J Med Sci.* 2004;20(6):273-8.
31. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. *Can J Urol.* 2012 Oct; 19 Suppl 1:10-17.
32. Richard A, Chaidir A. Validation of Indonesian Version of IPSS. *Indonesian Journal of Urology.* 2014;21(1).
33. Andika A, Yogi I, Hari N. Comparison between visual prostate symptom score and international prostate symptom score in males older than 40 years in rural Indonesia. *Prostate Int.* 2014;2(4):176-181.
34. Lim CF, Buchan NC. Measurement of serum PSA as a predictor of symptoms scored on the IPSS for patients with benign prostatic hyperplasia. *N Z Med J.* 2014;127(1389):17-24.
35. D'Silva KA, Dahm P, Wong CL. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. *JAMA.* 2014;6;312(5):535-42. Doi: 10.1001/jama.2014.5555.

36. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GM, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. *J Urol*;2000:13-20.
37. Wijanarko S, Gardjito W, Hardjowijoto S, et al. Studi analitik pengaruh pemasangan kateter terhadap kadar antigen spesifik prostat dalam darah pada pasien hiperplasia prostat jinak dengan retensi urine. *JURI*. 2003;10: 1-8.
38. Prasetyawan W, Sumardi R. Korelasi antara volume residu urine dan adanya obstruksi pada penderita dengan simtom BPH dengan menggunakan pressure flow study. *JURI*. 2003;10: 19-21.
39. Lukacs B, Cornu JN, Aout M, Tessier N, Hodée C, Haab F, et al. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study. *Eur Urol*;2013: 64(3):493-501.
40. Kiliç M, Özdemir A, Altinova S, Et Al. What is the best radiological method to predict the actual weight of the prostate? *Turk J Med Sci*. 2014;44:31-35.
41. Taufiq N, Basuki B, Besut D, Kurnia P, Paksi S. IPP As Predictive Factor for Acute Urinary Retention in BPH Patients. *Indonesian Journal of Urology*;2014;21(1).
42. Keong Tatt Foo. Pathophysiology of clinical benign prostatic hyperplasia. *Asian Journal of Urology*;2017;4(3):152 – 157.
43. Tjahjodjati, Santoso J. Relationship between Prostate-Urethral angle, Intravesical prostatic Protrusion, International Prostatic Symptom Score, and Uroflowmetry in Benign Prostatic Hyperplasia Patients. *International Journal of Integrated Health Sciences*. 2015;3(2):50-4
44. Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J; International Consultation on New Developments in Prostate Cancer and Prostate Diseases.

- Evaluation and treatment of lower urinary tract symptoms in older men. *J Urol*. 2013 Jan;189(1 Suppl):S93-S101. Doi: 10.1016/j.juro.2012.11.021.
45. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. *Eur Urol*. 2014 Jun 24. Pii: S0302-2838(14)00538-7. Doi: 10.1016/j.eururo.2014.06.017. [Epub ahead of print]
46. Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. *Curr OpinUrol*. 2012 Jan;22(1):34-9. Doi: 10.1097/MOU.0b013e32834d8e87.
47. Lepor H. Alpha Blockers for the Treatment of Benign Prostatic Hyperplasia;2007:Rev *Urol* 9(4): 181–190.
48. Kono M, Nakamura Y, Ishiura Y, et al. Central muscarinic receptor subtypes regulating voiding in rats. *J Urol* 2006 Jan;175(1):353-7. <http://www.ncbi.nlm.nih.gov/pubmed/16406941>.
49. Abrams P, Kaplan S, De Koning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. *J Urol* 2006 Mar;175(5):999-1004. <http://www.ncbi.nlm.nih.gov/pubmed/16469601>.
50. Greco KA, McVary KT. The role of combination medical therapy in benign prostatic hyperplasia. *Int Jimpot Res*. 2008 Dec;20 Suppl 3: S33-43. Doi: 10.1038/ijir.2008.51. <http://www.ncbi.nlm.nih.gov/pubmed/19002123>.
51. Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms

Suggestive of Benign Prostatic Obstruction (BPH Guidelines). Eur Urol;2004;46:547-54

52. Sahito RA, Pirzada AJ, Qureshi MA, et al. A Comparative Study of Trans Urethral Resection Versus Trans Urethral Incision for Small Size Obstructing Prostate. Journal of Surgery Pakistan (International);2012;17(3):93-97.
53. Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012 May;61(5):917-25. <http://www.ncbi.nlm.nih.gov/pubmed/22297243>.
54. Topazio L, Perugia C, De Nunzio C, Gaziev G, Lacovelli V, Bianchi D, Vespasiani G. Intravesical prostatic protrusion is a predictor of alpha blockers response: result from an observational study. BMC urol;2018;18(6)
55. Yu mi seo, Hyung Jee kim. Impact of intravesical Protrusion of the prostate in the treatment of Lower urinary Tract Symptoms/ Benign Prostatic hyperplasia of Moderate size by Alpha Receptor Antagonist. International neurourology journal;2012;16(4):187-90
56. Lieber MM, JacobsonDJ, Mcgree ME,etc. Intravesical prostatic protrusion in men in Olmsted country, minnesota. J Urol;2009;182:2819-24
57. Park HY, Lee JY, Park SY, etc. Efficacy of alpha blocker treatment according to the degree of intravesical prostatic protrusion detected by transrectal ultrasonography in patients with benign prostatic hyperplasia. Korean J Urol;2012;53(2)::92-7
58. Lim KB, Ho H, Poo KT etc. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic specific antigen in the evaluation of bladder outlet obstruction. Int j Urol;2006;13(12);1509-13

59. As'ari, Sabital alif. Hubungan atra derajat Intravesical Prostatic Protrusio dengan Qmax, volume prostat, dan internasional prostate symptom score pada pasien BPH dengan LUTS tanpa komplikasi. Indonesian Journal of Urology;2009:6(2).

